Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.
Danny Nguyen, MD
Advertisement
Danny Nguyen, MD, is a medical oncologist and hematologist at City of Hope National Medical Center in Duarte, California.
Articles by Danny Nguyen, MD
The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol
3
Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL
4
HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD
5